C12Y 113/12007
Photinus-luciferin 4-monooxygenase , i.e. firefly-luciferase
Official title: Photinus-luciferin 4-monooxygenase (ATP-hydrolysing) (1.13.12.7), i.e. firefly-luciferase
C12Y113/12007 (Photinus-luciferin 4-monooxygenase , i.e. firefly-luciferase) appears on 280 US grants and 412 published applications in this corpus.
Search patents in C12Y- Granted patents
- 280
- Published applications
- 412
- Assignees
- 124
- Inventors
- 471
- Latest grant
- 30 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 3 | 0 |
| 1994 | 3 | 0 |
| 1995 | 0 | 0 |
| 1996 | 4 | 0 |
| 1997 | 5 | 0 |
| 1998 | 2 | 0 |
| 1999 | 2 | 0 |
| 2000 | 4 | 0 |
| 2001 | 4 | 0 |
| 2002 | 2 | 0 |
| 2003 | 1 | 4 |
| 2004 | 2 | 3 |
| 2005 | 1 | 4 |
| 2006 | 1 | 1 |
| 2007 | 3 | 16 |
| 2008 | 0 | 17 |
| 2009 | 10 | 11 |
| 2010 | 14 | 13 |
| 2011 | 7 | 10 |
| 2012 | 6 | 10 |
| 2013 | 3 | 7 |
| 2014 | 8 | 47 |
| 2015 | 17 | 26 |
| 2016 | 25 | 37 |
| 2017 | 29 | 34 |
| 2018 | 21 | 31 |
| 2019 | 25 | 33 |
| 2020 | 22 | 27 |
| 2021 | 10 | 16 |
| 2022 | 14 | 13 |
| 2023 | 13 | 15 |
| 2024 | 5 | 14 |
| 2025 | 6 | 9 |
| 2026 | 7 | 14 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Lipids and lipid nanoparticle formulations for delivery of nucleic acids30 Jun 2026US 12,667,627 B2Acuitas Therapeutics, Inc.
- DNA vaccines16 Jun 2026US 12,655,477 B2Touchlight IP Limited
- Detection of environmental influences by bioluminescence2 Jun 2026US 12,644,104 B2Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen
- Auto-induction regulatory system based on quorum sensing and application thereof21 Apr 2026US 12,606,835 B2Ocean Universrry of China
- Isolated nucleic acid molecule and application thereof10 Feb 2026US 12,544,461 B2Gritgen Therapeutics Limited
- Photoswitch protein8 Oct 2026US 2026/0308556 A1Kanagawa Institute of Industrial Science and Technology
- Modified rna with decreased immunostimulatory properties24 Sep 2026US 2026/0284227 A1CureVac AG
- Engineered Luciferases and Luciferin Substrates27 Aug 2026US 2026/0250737 A1Monod Bio, Inc.
- Methods and systems for engineering cells and for target validation30 Jul 2026US 2026/0218150 A1Bristol-Myers Squibb Company
- Materials and methods for characterizing potency23 Jul 2026US 2026/0209795 A1Encoded Therapeutics, Inc.
Most cited
By later US patents
- Delivery of exogenous DNA sequences in a mammal1,218US 5,580,859 AVical Incorporated · 1996
- Induction of a protective immune response in a mammal by injecting a DNA sequence885US 5,589,466 AVical Incorporated · 1996
- Generation of antibodies through lipid mediated DNA delivery427US 5,703,055 AVical Incorporated · 1997
- Induction of a protective immune response in a mammal by injecting a DNA sequence362US 6,214,804 B1Vical Incorporated · 2001
- DNA sequences encoding coleoptera luciferase activity233US 5,674,713 AThe Regents of the University of California · 1997